@codyontrt's testosterone blood work update, fact-checked
Quick answer
Cody presents with a pre-treatment total testosterone of approximately 260 ng/dL, consistent with primary hypogonadism by Endocrine Society criteria, now treated to 904 ng/dL total testosterone at 22 weeks. His estradiol of 61 pg/mL exceeds the standard male reference range of 10-40 pg/mL and may indicate increased aromatization, a common occurrence at higher testosterone levels, particularly in patients with higher adipose tissue or without aromatase inhibitor co-administration. Clinical review of his current protocol and consideration of estradiol management strategies is appropriate given the elevated reading.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @codyontrt actually say?
At week 22 of testosterone replacement therapy, Cody shared his bloodwork: total testosterone at 904 ng/dL, free testosterone at 198 pg/mL, and estradiol at 61 pg/mL. He noted his pre-TRT total testosterone was around 260 ng/dL. He flagged the estrogen as "definitely high" but said he feels no symptoms from it, and plans to discuss it with his clinic doctor. That's a reasonably responsible approach, and the self-awareness about estrogen is worth acknowledging.
His framing was personal and anecdotal, not prescriptive. He didn't recommend a dose or tell viewers to replicate his protocol. That matters when evaluating how potentially harmful this content actually is.
Does the science back this up?
Mostly, yes, with one significant caveat around the estrogen number. Total testosterone at 904 ng/dL sits comfortably within the therapeutic target range most endocrinology guidelines aim for. Free testosterone at 198 pg/mL is on the higher end but not alarming in isolation. The estradiol reading deserves more serious attention than Cody gave it.
The Endocrine Society's clinical practice guidelines (Bhasin et al., 2018, Journal of Clinical Endocrinology and Metabolism) define a normal male estradiol range as roughly 10-40 pg/mL. At 61 pg/mL, Cody is meaningfully above that. Elevated estradiol in men on TRT is associated with gynecomastia, fluid retention, and in some research, cardiovascular and mood effects. A study by Finkelstein et al. (2013, New England Journal of Medicine) demonstrated that estrogen plays a complex role in male physiology, including bone density and libido, so blanket suppression isn't the answer. But 61 pg/mL warrants a real clinical conversation, not just a shrug because symptoms haven't appeared yet.
What did they get wrong (or right)?
Cody got the general self-monitoring right. Getting bloodwork done at week 22 and tracking total testosterone, free testosterone, and estradiol is exactly what responsible TRT use looks like. His pre-TRT baseline of around 260 ng/dL is consistent with clinical hypogonadism, which typically requires a threshold below 300 ng/dL for diagnosis (Bhasin et al., 2018).
Where he undersells the issue is the line "I don't feel any negatives from that high estrogen." This is a common and genuinely risky assumption. Symptoms of elevated estradiol, particularly cardiovascular strain and early gynecomastia, are not always immediately apparent. A paper by Laughlin et al. (2008, American Journal of Epidemiology) found that both low and high estradiol in men correlated with increased mortality risk, which is not a reason to panic, but it is a reason to not dismiss a number of 61 pg/mL simply because you feel fine today. Feeling fine is not a biomarker.
What should you actually know?
If you're on TRT and watching this video for guidance, here's what actually matters. First, your bloodwork timing is everything. Cody tested three days post-injection, which captures a near-peak reading for cypionate or enanthate. Testing at trough, closer to injection day, gives a different picture. Neither is wrong, but your clinic needs to know when in your cycle you tested.
Second, estradiol at 61 pg/mL is not a medical emergency, but it is a signal. Aromatase inhibitors are sometimes used to manage this, but they carry their own risks, including over-suppression that tanks estrogen too far, which also causes problems (Finkelstein et al., 2013). This is genuinely a conversation for a prescribing clinician, not a TikTok comment section.
Third, the absence of symptoms does not equal the absence of risk. This is the single most important thing to understand about hormonal management. Bloodwork exists precisely because the body compensates quietly before it doesn't.
- Total testosterone of 904 ng/dL is within accepted therapeutic range for treated hypogonadism.
- Estradiol at 61 pg/mL exceeds standard male reference ranges and warrants clinical evaluation.
- Symptom-free does not confirm a safe hormonal state, especially for cardiovascular markers.
- Testing timing relative to injection cycle significantly affects how results should be interpreted.
Bottom line: should you take anything from this video?
Cody's video is more responsible than most TRT content on TikTok. He shares real numbers, acknowledges a potential problem, and defers to a doctor rather than self-medicating. That's a lower bar than it should be, but he clears it. The concern is that viewers might absorb the "I feel fine so it's fine" framing about elevated estradiol and apply it to their own situations without the same follow-through. Feeling good at week 22 is not a clean bill of health. It's a starting point for the conversation he says he's going to have.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @codyontrt's testosterone blood work update, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Cardiovascular Safety of Testosterone-Replacement Therapy
TRAVERSE trial anchor for cardiovascular-safety discussions in appropriately diagnosed men.
PubMed
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline
Guideline anchor for diagnosis, monitoring, contraindications, and appropriate TRT framing.
PubMed
NAD+ metabolism and its roles in cellular processes during ageing
Core review for NAD+ decline, mitochondrial function, DNA repair, and aging biology.
PubMed
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
Human NMN source for metabolic claims while keeping population limits clear.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
@codyontrt's testosterone blood work update, fact-checked is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this testosterone and trt video claims cluster
Best for searchers turning TRT social claims into a safer lab-backed provider discussion.
Claim verdict
The useful answer behind this video
Claim being checked
Cody presents with a pre-treatment total testosterone of approximately 260 ng/dL, consistent with primary hypogonadism by Endocrine Society criteria, now treated to 904 ng/dL total testosterone at 22 weeks.
FormBlends verdict
Cody presents with a pre-treatment total testosterone of approximately 260 ng/dL, consistent with primary hypogonadism by Endocrine Society criteria, now treated to 904 ng/dL total testosterone at 22 weeks. His estradiol of 61 pg/mL exceeds the standard male reference range of 10-40 pg/mL and may indicate increased aromatization, a common occurrence at higher testosterone levels, particularly in patients with higher adipose tissue or without aromatase inhibitor co-administration. Clinical review of his current protocol and consideration of estradiol management strategies is appropriate given the elevated reading.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Cody presents with a pre-treatment total testosterone of approximately 260 ng/dL, consistent with primary hypogonadism by Endocrine Society criteria, now treated to 904 ng/dL total testosterone at 22 weeks. His estradiol of 61 pg/mL exceeds the standard male reference range of 10-40 pg/mL and may indicate increased aromatization, a common occurrence at higher testosterone levels, particularly in patients with higher adipose tissue or without aromatase inhibitor co-administration. Clinical review of his current protocol and consideration of estradiol management strategies is appropriate given the elevated reading.
- Endocrine Society guidelines (Bhasin et al., 2018) place the clinical hypogonadism threshold below 300 ng/dL total testosterone, making Cody's pre-TRT baseline of ~260 ng/dL consistent with a legitimate diagnosis.
- A total testosterone of 904 ng/dL tested three days post-injection reflects a near-peak reading, not a trough. Trough testing, done just before the next injection, gives a more conservative picture of baseline hormonal status.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Endocrine Society guidelines (Bhasin et al., 2018) place the clinical hypogonadism threshold below 300 ng/dL total testosterone, making Cody's pre-TRT baseline of ~260 ng/dL consistent with a legitimate diagnosis.
- A total testosterone of 904 ng/dL tested three days post-injection reflects a near-peak reading, not a trough. Trough testing, done just before the next injection, gives a more conservative picture of baseline hormonal status.
- Standard male estradiol reference ranges are approximately 10-40 pg/mL. Cody's reading of 61 pg/mL exceeds this by over 50% and is not something to dismiss based on feeling fine.
- Finkelstein et al. (2013, NEJM) showed estrogen plays a meaningful role in male bone density, libido, and body composition, so the goal is not to eliminate estradiol but to manage it within a functional range.
- Laughlin et al. (2008, American Journal of Epidemiology) found both low and high estradiol associated with increased mortality risk in men, which is a reason for clinical monitoring, not panic, but also not complacency.
- Aromatase inhibitors can reduce elevated estradiol in TRT patients but carry risks of over-suppression. Any adjustment to a hormonal protocol requires clinician oversight, not self-management based on symptom feel.
- Bloodwork timing relative to injection cycle significantly affects how results are interpreted. Patients should tell their clinic exactly when in their cycle they tested to get an accurate read of their protocol's effect.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
CodyOnTRT · TikTok creator
10.5K views on this video
Week 22 of TRT and I was finally able to get my blood work done! #trt #testosterone #lowtestosterone #testosteronebooster #gym
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by CodyOnTRT, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.